Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
Open Access
- 12 March 1999
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 79 (11) , 1746-1751
- https://doi.org/10.1038/sj.bjc.6690278
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Very high-dose chemotherapy with autologous peripheral stem cell support in advanced ovarian cancerEuropean Journal Of Cancer, 1995
- Co‐expression of urokinase, urokinase receptor and PAI‐1 is necessary for optimum invasiveness of cultured lung cancer cellsInternational Journal of Cancer, 1995
- Plasminogen activators and plasminogen activator inhibitors in blood and tumour fluids of patients with ovarian cancerEuropean Journal Of Cancer, 1994
- The plasminogen‐activation system in ovarian tumorsInternational Journal of Cancer, 1993
- Entwicklungen in der Therapie des fortgeschrittenen Ovarialkarzinoms FIGO IIIGeburtshilfe und Frauenheilkunde, 1993
- Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer PrognosisJournal of the American Statistical Association, 1992
- Flow cytometric analysis of nuclear DNA content in ovarian tumors association of ploidy with tumor type, histologic grade, and clinical stageCancer, 1992
- UROKINASE-TYPE PLASMINOGEN ACTIVATOR ANTIGEN AND EARLY RELAPSE IN BREAST CANCERThe Lancet, 1989
- Cytoreductive Surgery in Ovarian CarcinomaObstetrics & Gynecology, 1986
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958